Analyst Update: GoPro, Isis Pharmaceuticals, Yandex

Analysts are weighing in today on portable camera maker GoPro Inc (NASDAQ:GPRO), drugmaker ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS), and Russian search specialist Yandex NV (NASDAQ:YNDX). Here's a quick look at today's brokerage notes on GPRO, ISIS, and YNDX.

• GPRO is down 5.2% today to trade at $51.73, after Citigroup slashed its target price to $59 from $94 while reiterating its "neutral" stance on the stock. What's more, GoPro Inc has shed about 18.2% year-to-date, recently hit by Apple Inc.'s (NASDAQ:AAPL) new action-camera patent, and will release earnings after the close tomorrow. Unsurprisingly, short sellers have flocked to the equity, with nearly 29% of GPRO's float sold short (about 14.3 million shares). Also, two-thirds of covering analysts rate the stock a "hold" or worse, and GPRO's consensus 12-month price target of $79.73 stands at a 54.1% premium to current trading levels.


• Shares of ISIS have lost about 4.7% around midday to hit $61.67, following yesterday's announcement that the company's experimental type 2 diabetes drug doesn't perform as quickly as anticipated. In response, Piper Jaffray cut its price target to $68 from $81, and downgraded the stock to "neutral" from "overweight." Elsewhere, bearish sentiment in ISIS Pharmaceuticals, Inc.'s options pits is nearing a pessimistic peak. Specifically, ISIS' 10-day International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) put/call volume ratio of 1.76 sits just 9 percentage points from an annual high.


• YNDX is up about 0.4% in intraday trading at $15.69, even after Renaissance Capital lowered its price target to $19.20 from $33.80 while underscoring a "buy" rating. On the charts, the stock has been a technical laggard, losing 57.2% year-over-year. However, sentiment in the options pits is bullish, with Yandex NV's 10-day ISE/CBOE/PHLX call/put volume ratio of 14.93 sitting higher than 95% of all other readings taken over the last year. The brokerage bunch is optimistic as well, with all eight covering analysts doling out a "buy" or better rating on the stock.